BioInformant

Your Global Leader in Stem Cell Market Research

Home » StemBioSys

StemBioSys and Cartox Announce Publication of Research Demonstrating CELLvoTM Matrix Plus Significantly Enhances the Functionality of hiPSC Cardiomyocytes

By

Matrix Plus promotes functional and structural maturation of hiPSC-CMs in seven days compared to partial maturation obtained within 30 to 100 days with current approaches

SAN ANTONIO and ANN ARBOR, Mich., Nov. 9, 2020 — StemBioSys, Inc. (StemBioSys) and CarTox, Inc. (Cartox) announced today the publication of research in Nature Scientific Reports demonstrating that CELLvo™ Matrix Plus, an extracellular matrix (ECM) technology derived from human perinatal stem cells, supports rapid functional and structural maturation of human induced pluripotent stem cell derived cardiomyocytes (hiPSC-CMs) in culture and enables high throughput cardiotoxicity screening using mature human cardiomyocytes.
[Read more…]

Introducing the Dawn of MSCs with RoosterBio Founder, Jon Rowley

By

RoosterBioFounded by Dr. Jon Rowley, RoosterBio is a privately held stem cell tools and technology company focused on accelerating the development of a sustainable regenerative medicine industry. Its products are high volume, affordable, and well-characterized adult human mesenchymal stem/stromal cells (hMSCs) paired with highly engineered media systems. I had the honor of interviewing Dr. Jon Rowley, who is now the CTO of RoosterBio.

In this interview, we explore RoosterBio’s recent product launches, collaborations, achievements and future trajectory.    [Read more…]

StemBioSys Expands its Footprint into Houston

By

StemBioSysSAN ANTONIO – StemBioSys Inc. announced today that it will add a second office location. StemBioSys’s new location in Houston will be located in Johnson & Johnson Innovation, JLABS (JLABS) at the Texas Medical Center (JLABS @ TMC). JLABS is a life science innovation center, providing a flexible environment for start-up companies pursuing new technologies and research platforms to advance medical care. Through a “no strings attached” model, Johnson & Johnson Innovation does not take an equity stake in the companies occupying JLABS and the companies are free to develop products -either on their own, or by initiating a separate external partnership with JJI or any other company.

StemBioSys President & CEO, Bob Hutchens stated, “We are pleased to be a resident company at JLABS @ TMC and look forward to taking full advantage of the opportunity to be part of the biotech community in Houston through our virtual presence at JLABS.” Hutchens also noted that the primary location for the company would remain in San Antonio. “We are committed to the San Antonio community. All of our employees will remain based in San Antonio. There are a number of advantages we enjoy because of our San Antonio location.” [Read more…]

StemBioSys Licenses Additional Technology From UT Health San Antonio To Expand Existing Portfolio on Stem Cell-Enabling Technologies

By

SAN ANTONIO – StemBioSys Inc. announced that it has licensed additional technology from UT HealthTM San Antonio that expands the company’s intellectual property portfolio aimed at enabling the expansion of adult stem cells for therapeutic use.

To date StemBioSys has converted three pending patents originally licensed from UT HealthTM San Antonio into eight issued and a dozen pending patent applications. The latest technology is aimed at the enrichment and amplification of highly potent stem cells from elderly individuals. [Read more…]

BioInformant's World-Class Clients